New Selenoderivatives as Antitumoral Agents
November 2011
in “
InTech eBooks
”
Studysummary This review explores prostate cancer risk factors, screening, treatment, and potential roles of selenium and 5-alpha reductase inhibitors in risk reduction but presents no new clinical data.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document discussed the potential of selenium (Se) as a promising treatment for prostate cancer (PC), highlighting its ability to inhibit PC through multiple mechanisms. Despite the prevalence of PC and the availability of treatments like hormone ablation therapy, radiation, and surgery, these options did not offer a cure and had significant side effects. The document emphasized the importance of prevention strategies, including pharmacological and dietary interventions, to reduce PC morbidity and mortality. Selenium, as a micronutrient, emerged as a significant focus in clinical trials, showing promise in controlling the development of PC.
